MARKET

LMDXW

LMDXW

Lumiradx Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9375
0.00
0.00%
Opening 16:00 06/28 EDT
OPEN
--
PREV CLOSE
0.9375
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
2.360
52 WEEK LOW
0.5210
MARKET CAP
--
P/E (TTM)
-1.5165
1D
5D
1M
3M
1Y
5Y
BRIEF-LumiraDx Achieves CE Mark For Covid-19 Antigen Test On Amira, Its New Low-Cost Testing System
reuters.com · 06/09 13:50
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it has achieved CE Mark for the Amira System, its new testing system that provides low-cost, highly sensitive COVID-19 testing. The Amira Analyzer re...
PR Newswire · 06/09 12:33
BRIEF-LumiraDx Receives CE Mark For Two Multiplex Tests
reuters.com · 06/08 10:20
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
LumiraDx Limited (Nasdaq: LMDX) today announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete. These high-sensitivity and high-throughp...
PR Newswire · 06/08 10:03
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dime...
PR Newswire · 06/02 10:35
BRIEF-LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need For Diabetes Screening And Monitoring
reuters.com · 05/26 11:41
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its HbA1c test has achieved CE Marking. Used with the LumiraDx Platform, the test provides results in under seven minutes from sample application for the ...
PR Newswire · 05/26 09:30
BRIEF-Lumiradx Receives WHO Emergency Use Listing For Sars-Cov-2 AG Test
reuters.com · 05/20 09:16
More
No Data
Learn about the latest financial forecast of LMDXW. Analyze the recent business situations of Lumiradx Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About LMDXW
LumiraDx Limited is a diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched LumiraDx Platform, a platform which is an integrated system comprised of a small, point of care (POC) instrument, microfluidic test strips, and secure digital connectivity. The Company has developed five diagnostic tests which includes SARS-CoV-2 antigen, SARS-CoV-2 antigen pool, SARS-CoV-2 antibody, International Normalized Ratio (INR) test, and D-Dimer test. It has also developed two rapid COVID-19 reagent testing kits for use on open molecular systems, LumiraDx SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR. Its platform has a pipeline of approximately more than 30 tests in various stages of development for the community-based healthcare settings.

Webull offers kinds of LumiraDx Ltd stock information, including NASDAQ:LMDXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LMDXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LMDXW stock methods without spending real money on the virtual paper trading platform.